We are a cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90, or Hsp90, inhibitors and epothilones.
Company profile
Ticker
KOSN
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Icon • Syneos Health • Medpace • Incyte • Zymergen • OmniAb ...
SEC CIK
Corporate docs
IRS number
943217016
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
14 Aug 08
15-12G
Securities registration termination
26 Jun 08
25-NSE
Exchange delisting
26 Jun 08
SC 14D9/A
Tender offer solicitation (amended)
26 Jun 08
SC TO-T/A
Third party tender offer statement (amended)
26 Jun 08
SC 14D9/A
Tender offer solicitation (amended)
19 Jun 08
SC TO-T/A
Third party tender offer statement (amended)
19 Jun 08
8-K
Entry into a Material Definitive Agreement
29 May 08
SC 14D9
Tender offer solicitation
29 May 08
SC TO-T
Third party tender offer statement
29 May 08
Latest ownership filings
No filings